Asthma Therapeutics Market Growth And Segment Forecasts To 2020

Market Reports Center
One Stop Market Reaserch Shop
Asthma Therapeutics Market Share, Size, Emerging Trends and
Growth, Analysis, Overview and Forecasts 2016-2020
Technavio Announces the Publication of its Research Report – Global Asthma Therapeutics Market
Technavio recognizes the following companies as the key players in the global asthma therapeutics
market: AstraZeneca, Boehringer Ingelheim, F. Hoffmann-La Roche, GSK, Merck,
Other Prominent Vendors in the market are: ALK-Abello, Amgen, Array BioPharma, Asmacure, Astellas
Pharma, Axikin Pharmaceuticals, Chiesi Farmaceutici, Dynavax Technologies, Horizon Pharma, Hovione
Scientia, Invion, Ivax, Kissei Pharmaceutical, Kyowa Hakko Kirin, MediciNova, Mitsubishi Tanabe Pharma,
Mundipharma, Nycomed, Oxagen Limited, Palobiofarma, Pearl Therapeutics, Pharmaking, Pharmaxis,
Pulmagen Therapeutics, Regeneron Pharmaceuticals, Revalesio, RSPR Pharma AB, SAMA
Pharmaceuticals, Sanofi, Skyepharma, SolAeroMed, Stallergenes, Sterna Biologicals, Synairgen, Theron
Pharmaceuticals, UCB Pharma, Vectura, Verona Pharma, and Whanin Pharmaceutical.
Browse full report with TOC@
Commenting on the report, an analyst from Technavio’ s team said: “One of the key trends for market
growth will be innovative technologies for drug delivery. The industry's shift toward electronic systems
technology like smart technology and EHR brings the level of perspective and accessibility across
healthcare specialties. This reduces cost when administering expensive medications. Other recent
advances include integration of add-on devices such as spacers, breath-actuated devices, and valved
holding chambers in inhalers.
Market Reports Center
One Stop Market Reaserch Shop
They help in reducing oropharyngeal deposition of inhaled corticosteroids and minimizes side effects.
According to the report, one of the key drivers for market growth will be huge market potential for
mAbs. mAbs will have a high uptake for the treatment of asthma, owing to the development of target
specific drugs. mAbs blocking IgE are specifically approved for the treatment of allergic asthma.
Asthmatic patients with phenotypes of severe refractory asthma will benefit from these mAbs. mAbs
against immunoglobulin or specific cytokines, which are known to be important in the initiation or
persistence of asthmatic inflammation are being developed. Xolair was the first mAb approved for the
treatment of allergic asthma.
Further, the report states that once of the challenges for the market will be increased preference for
CAM. Individuals with allergic rhinitis and asthma tend to adopt alternative methods of treatment
instead of pharmacologic treatment. According to a 2016 report, in the US above 20% of the population
suffer from allergic diseases, including allergic asthma, allergic rhinitis, and atopic dermatitis, and more
than 42% of the people use CAM for these conditions. The use of CAM for allergic conditions is higher in
some European countries because of its better efficacy, favorable safety, and low cost of therapies.
The study was conducted using an objective combination of primary and secondary information
including inputs from key participants in the industry. The report contains a comprehensive market and
vendor landscape in addition to a SWOT analysis of the key vendors.
Request A Sample copy of This Report @
About Asthma Therapeutics
Increasing allergic rhinitis is a major factor for allergic asthma leading to increase in research for the
development of allergic immunotherapies for the treatment of asthma. The global asthma therapeutics
market will observe a moderate growth during the forecast period because of loss of patent exclusivity
of the major drugs, allowing the entry of generics into the market. This will lead to the erosion of the
market share of the major asthma drugs. However, the presence of late-stage pipeline molecules will
drive the market. An increase in the prevalence of asthma and the use of combination drugs will drive
the growth of the market during the forecast period.
Technavio’ s analysts forecast the global asthma therapeutics market to grow at a CAGR of 4.31% during
the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global asthma therapeutics
market for 2016-2020. To calculate the market size, Technavio considers the revenue generated from
the sales of brand-name, generic, and off-label drugs used for the prevention and treatment of asthma.
The report also considers the revenues to be generated from the sales of drugs that are expected to be
Market Reports Center
One Stop Market Reaserch Shop
launched into the market along with the decline in revenues from patent expiries of marketed drugs
during the forecast period.
The market is divided into the following segments based on geography:
• Americas
Technavio's report, Global Asthma Therapeutics Market 2016-2020, has been prepared based on an indepth market analysis with inputs from industry experts. The report covers the market landscape and its
growth prospects over the coming years. The report also includes a discussion of the key vendors
operating in this market.
To Get Discount On The Report @
Connect for more details:
Sam Collins
Market Reports Center
1-646-883-3044 (US)
[email protected]

According to the report, one of the key drivers for market growth will be huge market potential for mAbs. mAbs will have a high uptake for the treatment of asthma, owing to the development of target specific drugs.